Post-transcriptional and post-translational regulation of PTEN by transforming growth factor-β

Journal of Cellular Biochemistry

Volumn 106, Issue 6, 2009, Pages 1102-1112

  Yang, Yong ^a   Zhou, Feng ^a   Fang, Zengyu ^a   Wang, Liying ^a,b   Li, Zengxia ^a,b   Sun, Lidong ^a   Wang, Can ^a,b   Yao, Wantong ^a   Cai, Xiumei ^a   Jin, Jiawei ^a   Zha, Xiliang ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Coding sequence; Post transcriptional; PTEN; Smad; TGF 1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; DACTINOMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PTEN PHOSPHOHYDROLASE; RECOMBINANT FUSION PROTEINS; RNA STABILITY; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 66149158167     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22100     Document Type: Article

References (63)

1. Akhurst RJ. 2004. TGF beta signaling in health and disease. Nat Genet 36:790-792.
2. Akhurst RJ, Derynck R. 2001. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11:S44-S51.
3. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803-36810.
4. Barreau C, Paillard L, Osborne HB. 2005. AU-rich elements and associated factors: Are there unifying principles? Nucleic Acids Res 33:7138-7150.
5. Bascom CC, Wolfshohl JR, Coffey RJ, Jr., Madisen L, Webb NR, Purchio AR, Derynck R, Moses HL. 1989. Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol 9:5508-5515.
6. Bashirullah A, Cooperstock RL, Lipshitz HD. 2001. Spatial and temporal control of RNA stability. Proc Natl Acad Sci USA 98:7025-7028.
7. Beauchamp RD, Sheng HM, Alam T, Townsend CM, Jr., Papaconstantinou J. 1992. Posttranscriptional regulation of albumin and alpha-fetoprotein messenger RNA by transforming growth factor-beta 1 requires de novo RNA and protein synthesis. Mol Endocrinol 6:1789-1796.
8. Bernstein PL, Herrick DJ, Prokipcak RD, Ross J. 1992. Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Dev 6:642-654.
9. Cai T, Lei QY, Wang LY, Zha XL. 2000. . TGF-beta 1 modulated the expression of alpha 5 beta 1 integrin and integrin-mediated signaling in human hepatocarcinoma cells. Biochem Biophys Res Commun 274:519-525.
10. Chen CY, You Y, Shyu AB. 1992. Two cellular proteins bind specifically to a purine-rich sequence necessary for the destabilization function of a c-fos protein-coding region determinant of mRNA instability. Mol Cell Biol 12:5748-5757.
11. Chou YT, Yang YC. 2006. Post-transcriptional control of Cited2 by transforming growth factor beta. Regulation via Smads and Cited2 coding region. J Biol Chem 281:18451-18462.
12. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. 2007. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28:2321-2327.
13. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
14. Eberhardt W, Doller A, Akool el S, Pfeilschifter J. 2007. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 114:56-73.
15. Ebert MP, Fei G, Schandl L, Mawrin C, Dietzmann K, Herrera P, Friess H, Gress TM, Malfertheiner P. 2002. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 86:257-262.
16. Goberdhan DC, Wilson C. 2003. PTEN: Tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 12 Spec No 12(Spec No 2): R239-R248.
17. Grosset C, Chen CY, Xu N, Sonenberg N, Jacquemin-Sablon H, Shyu AB. 2000. A mechanism for translationally coupled mRNA turnover: Interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell 103:29-40.
18. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, Kontos CD, Rich JN. 2005. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res 65:11276-11281.
19. Hollams EM, Giles KM, Thomson AM, Leedman PJ. 2002. MRNA stability and the control of gene expression: Implications for human disease. Neurochem Res 27:957-980.
20. Javelaud D, Mauviel A. 2005. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: Implications for carcinogenesis. Oncogene 24:5742-5750.
21. Kim S, Domon-Dell C, Kang J, Chung DH, Freund JN, Evers BM. 2004. Downregulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop. J Biol Chem 279:4285-4291.
22. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS, Mak TW. 2005. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7:263-273.
23. Leslie NR, Downes CP. 2002. PTEN: The down side of PI 3-kinase signalling. Cell Signal 14:285-295.
24. Li DM, Sun H. 1997. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57:2124-2129.
25. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947. (Pubitemid 27148818)
26. Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, Wang LY, Zha XL. 2005. Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol 11:4472-4477.
27. Maehama T. 2007. PTEN: Its deregulation and tumorigenesis. Biol Pharm Bull 30:1624-1627.
28. Maehama T, Taylor GS, Dixon JE. 2001. PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu Rev Biochem 70:247-279.
29. Massague J. 1990. The transforming growth factor-beta family. Annu Rev Cell Biol 6:597-641.
30. Massague J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
31. Massague J, Blain SW, Lo RS. 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
32. Moustakas A, Pardali K, Gaal A, Heldin CH. 2002. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82:85-91.
33. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94:9052-9057.
34. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. 1998. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95:13513-13518.
35. Okahara F, Itoh K, Nakagawara A, Murakami M, Kanaho Y, Maehama T. 2006. Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell 17:4888-4895.
36. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. 2003. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22:4314-4332. (Pubitemid 36897963)
37. Parker R, Jacobson A. 1990. Translation and a 42-nucleotide segment within the coding region of the mRNA encoded by the MAT alpha 1 gene are involved in promoting rapid mRNA decay in yeast. Proc Natl Acad Sci USA 87:2780-2784.
38. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. 2001. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768.
39. Roberts AB, Wakefield LM. 2003. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100:8621-8623.
40. Schiavi SC, Wellington CL, Shyu AB, Chen CY, Greenberg ME, Belasco JG. 1994. Multiple elements in the c-fos protein-coding region facilitate mRNA deadenylation and decay by a mechanism coupled to translation. J Biol Chem 269:3441-3448.
41. Shyu AB, Greenberg ME, Belasco JG. 1989. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 3:60-72.
42. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. 2001. Regulation of PTEN transcription by p53. Mol Cell 8:317-325.
43. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
44. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. 2000. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156:585-594.
45. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617.
46. Tamura M, Gu J, Takino T, Yamada KM. 1999. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59:442-449.
47. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. 2004. Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 279:8567-8576.
48. ten Dijke P, Hill CS. 2004. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29:265-273.
49. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. 1997. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225.
50. Tourriere H, Chebli K, Tazi J. 2002. mRNA degradation machines in eukaryotic cells. Biochimie 84:821-837. (Pubitemid 35363466)
51. Vasudevan KM, Gurumurthy S, Rangnekar VM. 2004. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007-1021.
52. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. 2007. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67:10343-10350.
53. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I. 2001. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3:1124-1128.
54. Wakefield LM, Roberts AB. 2002. TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12:22-29.
55. Wang Q, Zhou Y, Wang X, Chung DH, Evers BM. 2007a. Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition. Cancer Res 67:7773-7781.
56. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. 2007b. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139.
57. Yamada KM, Araki M. 2001. Tumor suppressor PTEN: Modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375-2382.
58. Yang L, Steussy CN, Fuhrer DK, Hamilton J, Yang YC. 1996. Interleukin-11 mRNA stabilization in phorbol ester-stimulated primate bone marrow stromal cells. Mol Cell Biol 16:3300-3307.
59. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. 2008. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68:425-433.
60. Zavadil J, Bottinger EP. 2005. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24:5764-5774.
61. Zhang M, Pierce RA, Wachi H, Mecham RP, Parks WC. 1999. An open reading frame element mediates posttranscriptional regulation of tropoelastin and responsiveness to transforming growth factor beta1. Mol Cell Biol 19:7314-7326.
62. Zhang L, Yu Q, He J, Zha X. 2004. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem 262:25-33.
63. Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL. 2006. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 5:1008-1014.